> 9 I N N O V A T I O N %
lower plasma tenofovir
for TAF vs. TDF1
15 mm x 7 mm2
the smallest STR
in HIV treatment2–7
High efficacy maintained when switching to
Odefsey® from RPV/FTC/TDF at Week 488
How could the innovation of Odefsey® benefit your patients?
Roll over to
see more
Intended for Healthcare Professionals only. May 2017. ODE/IHQ/17-01//1006b
Click here for prescribing information
How could the innovation of
Odefsey® benefit your patients?
Roll over to
see more

Non-inferior efficacy when switching to
Odefsey® from Eviplera® (RPV/TDF/FTC),
94% vs. 94% at Week 48‡8

† HIV-1 RNA <50 copies/mL. ‡ Treatment difference -0.3%; 95% CI -4.2 to 3.7.

Delivers 91% lower plasma
tenofovir vs. TDF1

Odefsey® is the smallest
STR in HIV2–7

Markers of renal function and BMD
improved, in patients switching to Odefsey® from Eviplera®8

* vs. a TDF-based regimen.
Intended for Healthcare Professionals only. May 2017. ODE/IHQ/17-01//1006b
Click here for prescribing information and references